- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00240604
Prevention of Corticosteroid-induced Glucose Intolerance
September 13, 2011 updated by: Motti Muszkat, Hadassah Medical Organization
Treatment With Rosiglitazone for the Prevention of Glucose Intolerance in Patients Treated With Corticosteroids
Glucose intolerance is frequent and serious complication of corticosteroid therapy.
the aim of the study is to examine the hypothesis that co treatment with rosiglitazone can prevent glucose intolerance in patients treated with corticosteroids.
Study Overview
Detailed Description
Glucose intolerance is frequent and serious complication of corticosteroid therapy.
the aim of the study is to examine the hypothesis that co treatment with rosiglitazone can prevent glucose intolerance in patients treated with corticosteroids.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Organization
-
Contact:
- Arik Tzukert, DMD
- Phone Number: 0097226776095
- Email: arik@hadassah.org.il
-
Principal Investigator:
- Mordechai Muszkat, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- corticosteroid treatment
Exclusion Criteria:
- congestive heart failure pedal edema
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
plasma glucose concentration
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Arie BenYehuda, MD, Hadassah University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
October 1, 2015
Study Registration Dates
First Submitted
October 16, 2005
First Submitted That Met QC Criteria
October 16, 2005
First Posted (Estimate)
October 18, 2005
Study Record Updates
Last Update Posted (Estimate)
September 14, 2011
Last Update Submitted That Met QC Criteria
September 13, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7-29.10.04-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Intolerance
-
Yonsei UniversityNot yet recruitingType 2 Diabetes | Impaired Glucose Intolerance
-
University of California, IrvineUniversity of California, Davis; University of California, San FranciscoCompletedStress, Psychological | Pregnancy Related | Glucose Intolerance During PregnancyUnited States
-
Universidad de GranadaUnknownGlucose IntoleranceSpain
-
Merck Sharp & Dohme LLCCompleted
-
University of MichiganNorthern Michigan UniversityCompletedGlucose Intolerance
-
Albert Einstein College of MedicineAmerican Diabetes AssociationCompletedImpaired Glucose ToleranceUnited States
-
Vanderbilt UniversityTerminatedImpaired Glucose ToleranceUnited States
-
Guelph Food Research CentreGlycemic Index Laboratories, Inc; Ontario Bean Growers AssociationCompletedImpaired Glucose ToleranceCanada
-
Limerick BioPharmaWithdrawn
-
National Taiwan University HospitalUnknown
Clinical Trials on Rosiglitazone
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Centre Hospitalier Universitaire DijonCompleted
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2
-
GlaxoSmithKlineCompletedNeuropathy, DiabeticNetherlands
-
Medstar Health Research InstituteGlaxoSmithKlineTerminated
-
Baskent UniversityCompletedObesity | Type 2 Diabetes MellitusTurkey
-
Hospital Authority, Hong KongUnknownCardiovascular Diseases | Kidney Diseases | Chronic DiseaseChina
-
GlaxoSmithKlineCompletedAlzheimer's DiseaseUnited States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed